Kineta ROE 2014-2024 | KANT
Current and historical return on equity (ROE) values for Kineta (KANT) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Kineta ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2024-06-30 |
$-0.02B |
$-0.01B |
1050.00% |
| 2024-03-31 |
$-0.02B |
$-0.01B |
-900.00% |
| 2023-12-31 |
$-0.01B |
$0.00B |
-400.00% |
| 2023-09-30 |
$-0.06B |
$0.00B |
-1450.00% |
| 2023-06-30 |
$-0.06B |
$0.01B |
-1311.11% |
| 2023-03-31 |
$-0.07B |
$0.00B |
-1444.44% |
| 2022-12-31 |
$-0.06B |
$0.01B |
-853.33% |
| 2022-09-30 |
$0.00B |
$0.01B |
0.00% |
| 2022-06-30 |
$-0.00B |
$0.01B |
-40.00% |
| 2022-03-31 |
$-0.01B |
$0.01B |
-43.84% |
| 2021-12-31 |
$-0.01B |
$-0.01B |
-43.64% |
| 2021-09-30 |
$-0.07B |
$0.03B |
-148.31% |
| 2021-06-30 |
$-0.06B |
$0.04B |
-135.52% |
| 2021-03-31 |
$-0.05B |
$0.05B |
-111.23% |
| 2020-12-31 |
$-0.05B |
$0.06B |
-104.71% |
| 2020-09-30 |
$0.00B |
$0.04B |
9.02% |
| 2020-06-30 |
$-0.00B |
$0.05B |
-9.64% |
| 2020-03-31 |
$-0.02B |
$0.05B |
-47.29% |
| 2019-12-31 |
$-0.03B |
$-0.00B |
-49.40% |
| 2019-09-30 |
$-0.06B |
$0.07B |
-69.75% |
| 2019-06-30 |
$-0.07B |
$0.08B |
-82.14% |
| 2019-03-31 |
$-0.06B |
$0.10B |
-82.58% |
| 2018-12-31 |
$-0.06B |
$0.11B |
-90.71% |
| 2018-09-30 |
$-0.06B |
$0.04B |
-101.79% |
| 2018-06-30 |
$-0.05B |
$0.06B |
-95.07% |
| 2018-03-31 |
$-0.06B |
$0.06B |
-100.92% |
| 2017-12-31 |
$-0.06B |
$0.07B |
-104.89% |
| 2017-09-30 |
$-0.06B |
$0.04B |
-92.83% |
| 2017-06-30 |
$-0.05B |
$0.05B |
-71.97% |
| 2017-03-31 |
$-0.04B |
$0.07B |
-65.43% |
| 2016-12-31 |
$-0.04B |
$0.08B |
-62.81% |
| 2016-09-30 |
$-0.04B |
$0.09B |
-84.85% |
| 2016-06-30 |
$-0.03B |
$0.03B |
-176.00% |
| 2016-03-31 |
$-0.02B |
$0.04B |
-218.18% |
| 2015-12-31 |
$-0.02B |
$0.00B |
-2300.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
